Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes – 6 March 2014 – All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin‐based regimens.

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes – 6 March 2014 – All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin‐based regimens.

Jamuna Karkhanis, Elizabeth C. Verna, Matthew S. Chang, R. Todd Stravitz, Michael L. Schilsky, William M. Lee, Robert S. Brown – 5 March 2014

Stephen A. Geller – 5 March 2014

Albert Parés – 5 March 2014

John M. Vierling – 5 March 2014 – Watch a video presentation of this article

Christopher L. Bowlus – 5 March 2014 – Watch a video presentation of this article

Albert Parés – 5 March 2014 – Watch a video presentation of this article

Diego Vergani, Giorgina Mieli‐Vergani – 5 March 2014

Diego Vergani, Giorgina Mieli‐Vergani – 5 March 2014 – Watch a video presentation of this article